Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Consensus Recommendation of “Buy” by Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAGet Free Report) has been given an average rating of “Buy” by the six brokerages that are covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $37.17.

Several research firms recently issued reports on KNSA. Wedbush reissued an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective for the company.

View Our Latest Stock Analysis on Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Stock Performance

NASDAQ:KNSA opened at $22.97 on Thursday. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -164.06 and a beta of 0.48. Kiniksa Pharmaceuticals has a 52-week low of $16.56 and a 52-week high of $28.15. The stock has a fifty day moving average of $20.05 and a 200 day moving average of $22.10.

Kiniksa Pharmaceuticals (NASDAQ:KNSAGet Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The business had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s quarterly revenue was up 46.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.35 EPS. Equities analysts forecast that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Mark Ragosa sold 36,372 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total transaction of $809,277.00. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at $510,815.50. This represents a 61.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Eben Tessari sold 14,000 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the sale, the chief operating officer now owns 81,975 shares of the company’s stock, valued at $1,604,250.75. This represents a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 73,423 shares of company stock valued at $1,541,812 over the last 90 days. Insiders own 54.57% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Several institutional investors have recently bought and sold shares of KNSA. Quarry LP purchased a new stake in Kiniksa Pharmaceuticals during the 3rd quarter valued at about $50,000. Lazard Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals during the 4th quarter valued at about $61,000. KLP Kapitalforvaltning AS purchased a new stake in Kiniksa Pharmaceuticals during the 4th quarter valued at about $158,000. Bellevue Group AG purchased a new stake in Kiniksa Pharmaceuticals during the 4th quarter valued at about $160,000. Finally, Tower Research Capital LLC TRC raised its position in Kiniksa Pharmaceuticals by 117.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock valued at $168,000 after purchasing an additional 4,575 shares during the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile

(Get Free Report

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Further Reading

Analyst Recommendations for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.